A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).

NCT04826406 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma
Immune Checkpoint Inhibitors

Interventions

DRUG: Camrelizumab combined Apatinib regimen

Sponsor

Hunan Cancer Hospital

Collaborators

[object Object]